Drug for enhancing fibrinolytic system, and use therefor
AssigneeRenascience Co., Ltd.
InventorToshio MIYATA
Life of this patent
Estimating the term…
Abstract
Provided is a drug for enhancing the fibrinolytic system, comprising a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R1 is quinolyl, R2 is halogen, and R3 is carboxyl or a group that is biologically equivalent thereto; the active ingredient being administered at a daily dosage of 120 to 300 mg, and the drug being orally administered to a patient with a disease with a clinical condition that is expected to be improved by fibrinolytic enhancement.
Claims15
1-5. (canceled)
A method for improving a clinical condition that is expected to be improved by fibrinolytic enhancement or suppressing the aggravation of the clinical condition, the method comprising orally administering a pharmaceutical composition comprising a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
- wherein R
- 1 is quinolyl, R2 is halogen, and R3 is carboxyl or a group that is biologically equivalent thereto;
- to a patient with the clinical condition, preferably an adult patient aged 15 years or older,
- the pharmaceutical composition being orally administered at a rate such that the daily dosage for the patient is 120 to 300 mg, preferably 120 to 240 mg, in terms of the amount of compound (1).
A pharmaceutical composition for use in a method for improving a clinical condition that is expected to be improved by fibrinolytic enhancement or suppressing the aggravation of the clinical condition for a patient with the clinical condition, preferably an adult patient aged 15 years or older,
- the pharmaceutical composition comprising a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
- wherein R
- 1 is quinolyl, R2 is halogen, and R3 is carboxyl or a group that is biologically equivalent thereto;
- the method comprising orally administering the pharmaceutical composition to the patient at a rate such that the daily dosage of compound (1) is 120 to 300 mg, preferably 120 to 240 mg.
Use of a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof:
- wherein R
- 1 is quinolyl, R2 is halogen, and R3 is carboxyl or a group that is biologically equivalent thereto;
- for producing a drug for enhancing the fibrinolytic system,
- the drug for enhancing the fibrinolytic system being orally administered at a daily rate of 120 to 300 mg, preferably 120 to 240 mg, to a patient with a clinical condition that is expected to be improved by fibrinolytic enhancement.
Dependencies are inferred from the claim text.